Evidence map›Paper›PMID 39402681›Full record

ReviewJournal of ovarian research2024

Nanotechnology for boosting ovarian cancer immunotherapy.

Prabhjot Kaur, Santosh Kumar Singh, Manoj K Mishra, Shailesh Singh, Rajesh Singh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of ovarian research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Prabhjot KaurDepartment of Microbiology, Biochemistry and Immunology, Cancer Health Equity Institute, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA, 30310, USA.
Santosh Kumar SinghDepartment of Microbiology, Biochemistry and Immunology, Cancer Health Equity Institute, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA, 30310, USA.
Manoj K MishraCancer Biology Research and Training, Department of Biological Sciences, Alabama State University, Montgomery, AL, 36014, USA.
Shailesh SinghDepartment of Microbiology, Biochemistry and Immunology, Cancer Health Equity Institute, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA, 30310, USA.
Rajesh SinghDepartment of Microbiology, Biochemistry and Immunology, Cancer Health Equity Institute, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA, 30310, USA. rsingh@msm.edu.

Funding

The interplay of social and molecular determinants in lung cancer disparityR01CA256724 · NCI · MOREHOUSE SCHOOL OF MEDICINE · PI Brian M. Rivers, Rajesh Singh · 2022 to 2026
$2.3M
Targeted Nanotherapy for prostate cancerSC1CA193758 · NCI · MOREHOUSE SCHOOL OF MEDICINE · PI SINGH, RAJESH · 2014 to 2017
$1.4M
American Cancer Society CHERC-MSI-21-166-01-CHERC-MSINCI NIH HHS R01 CA256724NCI NIH HHS R01CA256724NCI NIH HHS SC1 CA193758NIH HHS SC1CA193758U.S. Department of Defense W81XWH1810429
6 · The paper itself

Abstract

Ovarian cancer, often referred to as the "silent killer," is notoriously difficult to detect in its early stages, leading to a poor prognosis for many patients. Diagnosis is often delayed until the cancer has advanced, primarily due to its ambiguous and frequently occurring clinical symptoms. Ovarian cancer leads to more deaths than any other cancer of the female reproductive system. The main reasons for the high mortality rates include delayed diagnosis and resistance to treatment. As a result, there is an urgent need for improved diagnostic and treatment options for ovarian cancer. The standard treatments typically involve debulking surgery along with platinum-based chemotherapies. Among patients with advanced-stage cancer who initially respond to current therapies, 50-75% experience a recurrence. Recently, immunotherapy-based approaches to enhance the body's immune response to combat tumor growth have shown promise. Immune checkpoint inhibitors have shown promising results in treating other types of tumors. However, in ovarian cancer, only a few of these inhibitors have been effective because the tumor's environment suppresses the immune system and creates barriers for treatment. This hampers the effectiveness of existing immunotherapies. Nonetheless, advanced immunotherapy techniques and delivery systems based on nanotechnology hold promise for overcoming these challenges.

Indexed as

ImmunotherapyNanotechnologyOvarian NeoplasmsFemaleHumansAdoptive cell therapyChimeric antigen receptor T-cell therapyClinical trialsImmune checkpoint blockadeMyeloid-derived suppressor cellsOvarian cancerPhotodynamic therapyPhotothermal therapyRegulatory T cellsTumor-associated macrophages

Identifiers

PMID39402681
PMCPMC11475952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.